2023 Guidance and Q3 Earnings

Focused on core therapy areas Two thirds of our R&D portfolio prevents and treats infectious diseases and HIV Infectious Diseases HIV Respiratory/ Immunology Oncology Arexvy MenABCWY Pneumococcal 24-valent mRNA Seasonal influenza/COVID-19 Shingrix GSK3943104 (Herpes simplex virus) GSK4348413 (gonorrhoea) gepotidacin Brexafemme Long-acting and ultra-long-acting N6LS (bNAb¹) 3rd generation INSTI² Capsid inhibitor depemokimab camlipixant Nucala (COPD³) GSK4532990 (NASH4) Ojjaara Jemperli cobolimab CD226 axis GSK3858279 (osteoarthritis pain) GSK1070806 (atopic dermatitis) tebipenem bepirovirsen Enabled by advanced technology and data platforms with targeted business development GSK Note: select pipeline programmes shown 1. Broadly neutralising antibody 2. Integrase strand transfer inhibitor 3. Chronic obstructive pulmonary disease 4. Non-alcoholic steatohepatitis a

View entire presentation